Drug maker Biocon will report its first quarter numbers of FY13 today. Analysts on an average expect the profit after tax to grow by 25% to Rs 88 crore from Rs 70 crore year-on-year.
Revenues are seen going up by 28% to Rs 568 crore and earnings before interest, tax, depreciation and amortisation (EBITDA) seen up by 21% at Rs 148 crore during the same period. But, operating profit margin is likely to fall by 150 basis points at 26% YoY while the same seen up by 70 basis points QoQ. On quarter-on-quarter basis, revenues are seen going down by 7% and profit after tax by 10%.They expect growth to be led by biopharma and contract research and manufacturing services (CRAMS). Biopharma would include growth from immunosuppresants / insulin / continued supplies of fidaxomicin. In case of CRAMS, company had mentioned seeing a good order inflow post Q4. In the fourth quarter of FY12, all verticals contributed. Biopharma was up by 48% YoY to Rs 381 crore (which was 70% of sales), domestic branded formulation (11%) was up by 34% to Rs 65 crore and CRAMS rose by 33% (19% of sales) to Rs 120 crore. Investors should watch out for licensing income. In the previous quarter, licensing income fell by 40% YoY Rs 46.3 crore.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
